International guidelines consider that NET given for 4 to 8 months is a validated treatment in postmenopausal women with hormone receptor-positive HR+/HER2-negative (HER2-) breast cancer to improve surgical outcome and to allow BCS [5,6]. This evidence concerns the gene ERBB2 and breast cancer.